Cara Therapeutic Stock Today
| CARA Stock | USD 0.69 0.04 5.48% |
Performance6 of 100
| Odds Of DistressLess than 39
|
Cara Therapeutic is trading at 0.69 as of the 19th of April 2024, a -5.48 percent decrease since the beginning of the trading day. The stock's open price was 0.73. Cara Therapeutic has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Cara Therapeutic are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of January 2014 | Category Healthcare | Classification Health Care |
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. The company has 54.66 M outstanding shares of which 2.58 M shares are currently shorted by private and institutional investors with about 3.51 trading days to cover. More on Cara Therapeutic
Moving together with Cara Stock
| 0.81 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.82 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Cara Stock
| 0.76 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.68 | ME | 23Andme Holding | PairCorr |
| 0.68 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.67 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.64 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
| 0.63 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 20th of May 2024
Cara Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cara Therapeutic's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cara Therapeutic or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Derek Chalmers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Marijuana (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Cara Operations Limited | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Marijuana, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Cara Therapeutic report their recommendations after researching Cara Therapeutic's financial statements, talking to executives and customers, or listening in on Cara Therapeutic's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cara Therapeutic. The Cara consensus assessment is calculated by taking the average forecast from all of the analysts covering Cara Therapeutic. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from Cara Therapeutic's historical financial statements, Cara Therapeutic is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Cara Therapeutic is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cara Therapeutic's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cara Therapeutic's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cara Therapeutic's financial leverage. It provides some insight into what part of Cara Therapeutic's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cara Therapeutic (CARA) is traded on NASDAQ Exchange in USA. It is located in 400 Atlantic Street, Stamford, CT, United States, 06901 and employs 55 people. Cara Therapeutic is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 38.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cara Therapeutic's market, we take the total number of its shares issued and multiply it by Cara Therapeutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cara Therapeutic conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 54.66 M outstanding shares of which 2.58 M shares are currently shorted by private and institutional investors with about 3.51 trading days to cover.
Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cara Therapeutic Probability Of Bankruptcy
Ownership AllocationCara Therapeutic retains a total of 54.66 Million outstanding shares. 30% of Cara Therapeutic outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Cara Ownership Details
Cara Stock Price Odds Analysis
What are Cara Therapeutic's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Cara Therapeutic jumping above the current price in 90 days from now is about 64.62%. The Cara Therapeutic probability density function shows the probability of Cara Therapeutic stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 5.4734 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cara Therapeutic will likely underperform. Additionally, cara Therapeutic has an alpha of 0.2721, implying that it can generate a 0.27 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Cara Therapeutic to move above the current price in 90 days from now is about 64.62 (This Cara Therapeutic probability density function shows the probability of Cara Stock to fall within a particular range of prices over 90 days) .
Cara Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Cara Therapeutic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cara Therapeutic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cara Therapeutic's value.| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2023-12-31 | 644.8 K | |
| Verition Fund Managegment, Llc | 2023-12-31 | 550 K | |
| Two Sigma Advisers, Llc | 2023-12-31 | 514.2 K | |
| Millennium Management Llc | 2023-12-31 | 467.2 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 419.7 K | |
| Northern Trust Corp | 2023-12-31 | 391.8 K | |
| Acadian Asset Management Llc | 2023-12-31 | 360.5 K | |
| Stifel Financial Corp | 2023-12-31 | 313.1 K | |
| Two Sigma Investments Llc | 2023-12-31 | 307.3 K | |
| Blackrock Inc | 2023-12-31 | 3.6 M | |
| Vanguard Group Inc | 2023-12-31 | 2.6 M |
Cara Therapeutic Historical Income Statement
Cara Therapeutic Income Statement is one of the three primary financial statements used for reporting Cara's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cara Therapeutic revenue and expense. Cara Therapeutic Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Cara Therapeutic's Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 1 M, whereas Selling General Administrative is forecasted to decline to about 15.7 M. View More FundamentalsCara Stock Against Markets
Picking the right benchmark for Cara Therapeutic stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cara Therapeutic stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cara Therapeutic is critical whether you are bullish or bearish towards Cara Therapeutic at a given time. Please also check how Cara Therapeutic's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cara Therapeutic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
Cara Therapeutic Corporate Directors
Cara Therapeutic corporate directors refer to members of a Cara Therapeutic board of directors. The board of directors generally takes responsibility for the Cara Therapeutic's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cara Therapeutic's board members must vote for the resolution. The Cara Therapeutic board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Harrison Bains | Director | Profile | |
| Jeffrey Ives | Director | Profile | |
| Dean Slagel | Independent Director | Profile | |
| Martin Vogelbaum | Independent Director | Profile |
How to buy Cara Stock?
Before investing in Cara Therapeutic, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cara Therapeutic. To buy Cara Therapeutic stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cara Therapeutic. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cara Therapeutic stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cara Therapeutic stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cara Therapeutic stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cara Therapeutic, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cara Stock please use our How to Invest in Cara Therapeutic guide.
Already Invested in Cara Therapeutic?
The danger of trading Cara Therapeutic is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cara Therapeutic is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cara Therapeutic. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cara Therapeutic is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.